Needham & Company reiterates a 'Buy' on Optimer Pharmaceuticals (OPTR); Dificid Approved by the FDA
Tweet
Share
E-mailGet Alerts OPTR Hot Sheet
Price: $12.78 --0%
Rating Summary:
3 Buy, 8 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
3 Buy, 8 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Needham & Company reiterates a 'Buy' on Optimer Pharmaceuticals (NASDAQ: OPTR), PT $19.
Needham analyst says, "Optimer announced late Friday that Dificid was approved by the FDA for the treatment of C. difficile-associated diarrhea (CDAD). The label incorporates an important benefit of the drug over vancomycin, namely lower recurrence of infection. In a conference call this morning, management announced the drug will be priced at a premium, $2800 per course ($140 * 2 tablets for 10 days)."
"We do not anticipate rapid market penetration, but believe there may be room for a positive surprise with the involvement of Cubist’s sales force in launching the drug. We expect Dificid to gain most traction once incorporated in treatment guidelines, which may occur in 2012/2013."
For more ratings news on Optimer Pharmaceuticals click here and for the rating history of Optimer Pharmaceuticals click here.
Shares of Optimer Pharmaceuticals closed at $12.98 yesterday.
Needham analyst says, "Optimer announced late Friday that Dificid was approved by the FDA for the treatment of C. difficile-associated diarrhea (CDAD). The label incorporates an important benefit of the drug over vancomycin, namely lower recurrence of infection. In a conference call this morning, management announced the drug will be priced at a premium, $2800 per course ($140 * 2 tablets for 10 days)."
"We do not anticipate rapid market penetration, but believe there may be room for a positive surprise with the involvement of Cubist’s sales force in launching the drug. We expect Dificid to gain most traction once incorporated in treatment guidelines, which may occur in 2012/2013."
For more ratings news on Optimer Pharmaceuticals click here and for the rating history of Optimer Pharmaceuticals click here.
Shares of Optimer Pharmaceuticals closed at $12.98 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Coherent (COHR) PT Raised to $420 at Needham
- Cellebrite (CLBT) PT Lowered to $12.50 at Needham
- Nu Holdings (Nubank) (NU) PT Raised to $19 at Needham
Create E-mail Alert Related Categories
Analyst Comments, FDARelated Entities
Needham & CompanySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
